Carlsmed (CARL)

Executive Summary

Carlsmed is a private medical technology company pioneering AI-enabled personalized spine surgery through its aprevo® platform. By leveraging patient-specific CT data and AI-driven 3D planning, the company designs and manufactures custom spinal fusion implants aimed at improving surgical outcomes and reducing healthcare costs. Founded in 2014 and headquartered in Carlsbad, California, Carlsmed addresses a significant unmet need in the $10B+ global spinal fusion market, where traditional implants often lead to suboptimal alignment and higher revision rates. The platform’s potential to standardize personalized care positions it as a disruptive innovator in orthopedics and neurosurgery. Despite being in a pre-commercial stage, the company has garnered a valuation of ~$270M, reflecting investor confidence in its technology and market opportunity. Key near-term milestones include regulatory clearances, clinical data generation, and commercial partnerships, which will be critical for validating the platform’s value proposition and driving adoption.

Upcoming Catalysts (preview)

• Q2 2026FDA 510(k) clearance for aprevo platform in additional spinal fusion indications70% success
• Q3 2026Publication of pivotal clinical study results demonstrating improved outcomes versus standard implants80% success
• Q4 2026Strategic partnership or distribution agreement with a major hospital network or spine device company60% success